Effect of Beta Blockers and Renin–Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
暂无分享,去创建一个
Seung‐Jung Park | S. Yun | Young-Hak Kim | Duk‐Woo Park | Jung‐Min Ahn | Cheol-Whan Lee | G. Park | Seung‐Whan Lee | J. Roh | Soo-Jin Kang | P. Lee | Seong-Wook Park | Mineok Chang | S. Yoon | Gyung-Min Park | Sung-Han Yoon
[1] Seungbong Han,et al. Trends, Characteristics, and Clinical Outcomes of Patients Undergoing Percutaneous Coronary Intervention in Korea between 2011 and 2015 , 2018, Korean circulation journal.
[2] Mao Chen,et al. Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. , 2015, The American journal of cardiology.
[3] W. Koch,et al. Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism. , 2014, Journal of the American College of Cardiology.
[4] Ju Han Kim,et al. Current trend of acute myocardial infarction in Korea (from the Korea Acute Myocardial Infarction Registry from 2006 to 2013). , 2014, The American journal of cardiology.
[5] C. Pepine,et al. Usefulness of Beta blockade in contemporary management of patients with stable coronary heart disease. , 2014, The American journal of cardiology.
[6] K. Alexander,et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. , 2014, The American journal of medicine.
[7] A. Peters,et al. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry). , 2014, The American journal of cardiology.
[8] W. Cunningham,et al. Secondary prevention for patients after a myocardial infarction: summary of updated NICE guidance , 2013, BMJ.
[9] K. Kotseva,et al. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey , 2013, European journal of preventive cardiology.
[10] C. Holman,et al. Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study , 2013, Heart.
[11] 苅尾 七臣,et al. ガイドライン解説 AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease : 2011 update , 2012 .
[12] Jean-Claude Tardif,et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry , 2012, European heart journal.
[13] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[14] John Spertus,et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.
[15] Y. Hayashi,et al. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. , 2010, The American journal of cardiology.
[16] K. Bestehorn,et al. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[17] J. Kaski,et al. Secondary Prevention After Acute Myocardial Infarction and Coronary Revascularisation: Focus on Angiotensin Converting Enzyme Inhibitors , 2008, Cardiovascular Drugs and Therapy.
[18] S. Jaber,et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. , 2008, JAMA.
[19] R. Collins,et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[20] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[21] M. Pfeffer,et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.
[22] S. Kernis,et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? , 2004, Journal of the American College of Cardiology.
[23] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[24] M. Gheorghiade,et al. &bgr;-Blockers in the Post-Myocardial Infarction Patient , 2002, Circulation.
[25] H. Dargie,et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.
[26] Salim Yusuf,et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.
[27] Nick Freemantle,et al. β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .
[28] R. Collins,et al. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.
[29] A. Ciampi,et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. , 1997, Journal of the American College of Cardiology.
[30] E. Aliot,et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.
[31] B. Magnani,et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .
[32] Dwight Lemon,et al. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .
[33] P. Serruys,et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. , 1986, Journal of the American College of Cardiology.
[34] P. Serruys,et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. , 1986, Journal of the American College of Cardiology.
[35] K. Swedberg,et al. EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.
[36] Jeroen J. Bax,et al. [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.
[37] K. Mahaffey,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .
[38] B. Gersh,et al. Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction , 2011 .
[39] N Freemantle,et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.
[40] B. Magnani,et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. , 1995, The New England journal of medicine.
[41] A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. , 1986, The New England journal of medicine.
[42] Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. , 1986, Lancet.